Pierre Fabre Laboratories receives EU marketing authorization for OBGEMSA™ (vibegron) to treat overactive bladder syndrome.
Pierre Fabre Laboratories receives European marketing authorization for OBGEMSA™ (vibegron) to treat overactive bladder syndrome, impacting over 70 million patients in Europe. The European Commission authorizes marketing of this innovative treatment, acquired through an exclusive license in 2022. The decision applies to EU member states, Iceland, Liechtenstein, and Norway.
June 28, 2024
5 Articles